Risk assessment and cost-effectiveness/utility analysis

Committee on the Institutional Means for Assessment of Risks to Public Health, National Research Council, 1983

Center for Biologics Evaluation and Research. Draft quantitative risk assessment of vCJD risk potentially associated with the use of human plasma-derived factor VIII manufactured under United States (US) licence from plasma collected in the US, <www.fda.gov/cber/blood/vcjdrisk.htm>; 2006.

Tan-Torres ET, Baltussen T, Adam R, Hutubessy R, Acharya A, Evans DB, Murray CJL, editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva, Switzerland: World Health Organization (WHO); 2003.

Custer, 2005, The cost-effectiveness of screening the U.S. blood supply for West Nile virus, Annals of Internal Medicine, 143, 486, 10.7326/0003-4819-143-7-200510040-00007

Busch, 2005, A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors, Transfusion, 45, 254, 10.1111/j.1537-2995.2004.04215.x

Kleinman, 2005, Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test, Transfusion, 45, 1247, 10.1111/j.1537-2995.2005.00198.x

Klein, 2007, Pathogen inactivation: making decisions about new technologies, Transfusion, 47, 2338, 10.1111/j.1537-2995.2007.01512.x

Weinstein, 1977, Foundations of cost-effectiveness analysis for health and medical practices, The New England Journal of Medicine, 296, 716, 10.1056/NEJM197703312961304

Gafni, 2003, NICE methodological guidelines and decision making in the National Health Service in England and Wales, Pharmacoeconomics, 21, 149, 10.2165/00019053-200321030-00001

Gold, 2007, Medicare and cost-effectiveness analysis: time to ask the taxpayers, Health Affairs (Project Hope), 26, 1399, 10.1377/hlthaff.26.5.1399

Hoch, 2004, Cost-effectiveness lessons from disease-modifying drugs in the treatment of multiple sclerosis, Expert Review of Pharmacoeconomics and Outcomes Research, 4, 11, 10.1586/14737167.4.5.537

Mauskopf, 2007, Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices–budget impact analysis, Value in Health, 10, 336, 10.1111/j.1524-4733.2007.00187.x

World Health Organization. Threshold values for intervention cost-effectiveness by region; 2000.

van Hulst, 2002, Pharmaco-economics of blood transfusion safety: review of the available evidence, Vox Sanguinis, 83, 146, 10.1046/j.1423-0410.2002.00198.x

Jackson, 2003, The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations, Transfusion, 43, 721, 10.1046/j.1537-2995.2003.00392.x

Marshall, 2004, Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States, Vox Sanguinis, 86, 28, 10.1111/j.0042-9007.2004.00379.x

AuBuchon, 1996, A cost-effectiveness analysis of the use of a mechanical barrier system to reduce the risk of mistransfusion, Transfusion, 36, 222, 10.1046/j.1537-2995.1996.36396182139.x

Korves, 2006, Cost-effectiveness of alternative blood-screening strategies for West Nile virus in the United States, PLoS Medicine, 3, 10.1371/journal.pmed.0030021

Cleemput, 2006, Balancing evidence and public opinion in health technology assessments: the case of leukoreduction, International Journal of Technology Assessment in Health Care, 22, 403, 10.1017/S0266462306051312

Boucher, 2007, Blood management: a primer for clinicians, Pharmacotherapy, 27, 1394, 10.1592/phco.27.10.1394

Bates, 2007, Reducing replacement donors in sub-Saharan Africa: challenges and affordability, Transfusion Medicine, 17, 434, 10.1111/j.1365-3148.2007.00798.x

Field, 2007, Transfusion in sub-Saharan Africa – does a western model fit?, Journal of Clinical Pathology, 60, 1073, 10.1136/jcp.2006.043505

Lackritz, 1992, Effect of blood transfusion on survival among children in a Kenyan hospital, Lancet, 340, 524, 10.1016/0140-6736(92)91719-O

Medina Lara, 2007, Laboratory costs of a hospital-based blood transfusion service in Malawi, Journal of Clinical Pathology, 58, 56, 10.1136/jcp.2004.018366

Jacobs, 1994, Secondary school students: a safer blood donor population in an urban with high HIV prevalence in East Africa, East African Medical Journal, 71, 720

Sarkodie, 2001, Screening for viral markers in volunteer and replacement blood donors in West Africa, Vox Sanguinis, 80, 142, 10.1046/j.1423-0410.2001.00023.x

Allain, 2005, Rapid tests for detection of viral markers in blood transfusion, Expert Review of Molecular Diagnostics, 5, 31, 10.1586/14737159.5.1.31

Owusu-Ofori, 2005, Pre-donation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings, Transfusion, 45, 133, 10.1111/j.1537-2995.2004.04279.x

Owusu-Ofori, 2005, Pre-donation testing of blood donors in resource-poor settings, Transfusion, 45, 1542, 10.1111/j.1537-2995.2005.00567.x

Heyns, 2006, The impact of individual donation NAT screening on blood safety – the South African experience, Vox Sanguinis, 1, 203

SA Department of Health. HIV and AIDS national strategic plan, 2007–2011.

Weusten, 2002, Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT, Transfusion, 42, 537, 10.1046/j.1537-2995.2002.00099.x

SANBS. Annual budget; 2007.

Swanevelder R. Statistician, SANBS.